Share This Page

 
Now on Twitter!

Follow us: ChinaBio

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Free White Paper
You are here: Home » About Us » Our Approach

Our Approach

Print
ChinaBio® Today provides investors and industry professionals with analysis and insights into China's biotech industry that cannot be found anywhere else.  All of our content is written by our editors, Greg B. Scott and Richard Daverman (supported by our research team in Shanghai), or guest authors and is exclusive to us... no rehashed articles or summaries with links to other sources.
 
From our headquarters in Zhangjiang Hi-Tech Park in Shanghai, the #1 life science park in China, and San Diego, California , we use a combination of “insider” and local knowledge, scientific understanding, and business and technical expertise to provide you with the critical information necessary to make better business and investment decisions in this exciting but highly complex market segment. 
  
What We Do
 
Our analysts monitor many industry sources for published and unpublished information on China's biotech industry that yield clues as to where the next big success – or failure – may be.  We also leverage insider information gathered through our personal networks and at several industry events we hold each year, including our ChinaBio® Investor Forums, ChinaBio® Partnering Forums, and ChinaBio® Leadership Retreats (see Upcoming Events). Then we add additional value through our commentary and analysis based on our years of experience to help you determine which companies may best meet your business or investment strategy. 
 
Our daily and week updates are free via email, but our paid subscription plans provide full access to all of our articles, including over 2000 articles in our archives.  See our Subscription Plans for a description of specific services included with our subscriptions.

Skepticism Pays
 
By nature, we are a skeptical group, in part because we review over 300 businesses each year – both public and private – and in part because we're on the ground in China and have seen the good and the bad.  We know that biotech is a risky and volatile industry to start with, and even more so in China, unless you know the pitfalls to avoid.  But the rewards can, of course, be huge, especially for the private equity investor. 
 
We are often called upon to write or lecture on investing in the life science industry, and we make this information readily available to our subscribers.  (See our Education Center.)
 
Winners and Losers
 
That’s where ChinaBio® Today comes in.  We help you separate the potential winners from the crowd and make wise business decisions based on knowledge that can only be gained from our editors and analysts. (Click here to learn more about Our Editors.)
 

 
ChinaBio® Today is published by ChinaBio® LLC, a premier consultancy and investment firm focused on in China's life science industry, and helping U.S. companies leverage the advantages of China's biotech industry.  Visit our web site www.ChinaBioLLC.com for more information. 
 
Login

  

    
   
ChinaBio® Events

ChinaBio® Partnering Forum 2012
May 23-24, 2012
Suzhou, China

>>More events...
Partner Events

China Healthcare Investment Conference 2012
March 13-15, 2012
Shanghai, China


Shanghai CEO Conference
March 28-29, 2012
Shanghai, China

>>More details...
Other Events

China Pharmaceutical R&D Summit
April 23-26, 2012
Shanghai, China


Biosimilars Asia 2012
April 23-26, 2012
Shanghai, China


Vaccines China 2012
April 23-26, 2012
Shanghai, China

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners